News

Ena Respiratory
05 Sep 2024

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

PDF Icon Download PDF
Read more
27 Aug 2024

ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051

Read more
08 May 2024

ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering INNA-051, a First-in-Class Antiviral Innate Immunomodulator

PDF Icon Download PDF
Read more
29 Apr 2024

ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator

PDF Icon Download PDF
Read more
11 Sep 2023

New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance

PDF Icon Download PDF

— INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection

Read more
29 Aug 2023

ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections

PDF Icon Download PDF

— $3.8 million DOD contract extension to fund non-clinical safety studies; three-month seasonal prophylaxis Phase 2b study in at-risk populations, – elderly with comorbidities, including chronic lung diseases and diabetes.

Read more
14 Feb 2023

Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

PDF Icon Download PDF

— Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration.  

Read more
30 Jan 2023

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

PDF Icon Download PDF

— ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations.

Read more
09 Jan 2023

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

PDF Icon Download PDF

Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats

Read more
13 May 2022

Safety and Tolerability of the Toll-Like Receptor (TLR)2/6 Agonist INNA-051 in Healthy Adults

PDF Icon Download PDF

2022 ATS International Conference May 13-18, 2022, San Francisco, USA

Read more
11 May 2022

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

PDF Icon Download PDF

ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™

Read more
15 Mar 2022

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

PDF Icon Download PDF

ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed
to boost innate immunity in patients at high risk of severe complications from respiratory infections

Read more
23 Feb 2022

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

PDF Icon Download PDF

INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD.

Read more
28 Sep 2021

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

PDF Icon Download PDF

ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity

Read more
13 Jul 2021

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

PDF Icon Download PDF
  • First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections
  • Company is recruiting study participants in the Sydney, Australia area
Read more
15 Jun 2021

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

PDF Icon Download PDF
  • Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051
  • Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D., to Board of Directors
Read more
18 Dec 2020

ENA Respiratory announces research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

PDF Icon Download PDF

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

Read more
28 Sep 2020

ENA Respiratory announces an extension of its Series A and positive COVID-19 ferret challenge study results

PDF Icon Download PDF

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal.

Read more